Compare · ABBV vs NTHI
ABBV vs NTHI
Side-by-side comparison of AbbVie Inc. (ABBV) and NeOnc Technologies Holdings Inc. (NTHI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and NTHI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $373.77B, about 3394.6x NTHI ($110.1M).
- Over the past year, ABBV is up 9.4% and NTHI is down 17.5% - ABBV leads by 26.9 points.
- NTHI has been more active in the news (19 items in the past 4 weeks vs 17 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 1 for NTHI).
- Company
- AbbVie Inc.
- NeOnc Technologies Holdings Inc.
- Price
- $211.38+3.47%
- $4.37+6.59%
- Market cap
- $373.77B
- $110.1M
- 1M return
- -2.79%
- -37.64%
- 1Y return
- +9.37%
- -17.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 17
- 19
- Recent ratings
- 25
- 1
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
- AbbVie upgraded by BofA Securities with a new price target
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports First-Quarter 2026 Financial Results
- AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
- RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
- EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
- AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
- AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
Latest NTHI
- President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)
- Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)
- CFO Garnett Keithly bought $1,614 worth of shares (300 units at $5.38), increasing direct ownership by 0.12% to 241,200 units (SEC Form 4)
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target
- President Heshmatpour Amir F bought $49,000 worth of shares (10,000 units at $4.90), increasing direct ownership by 0.33% to 3,052,000 units (SEC Form 4)
- SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results